All In Biotech

Drug Trial Radar · NCT03342053

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Last checked: Nov 19, 2026Latest source record: Mar 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

46

Actual

Start

Jan 2, 2018

Primary completion

Oct 8, 2019

Study completion Oct 8, 2019

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.

Conditions

  • Huntington's Disease

Interventions

  • RO7234292 (RG6042)Drug

    Intrathecal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse EventsTime frame: From baseline up to 18 months

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • The University of British Columbia; The Centre for Huntington Disease

    Vancouver, British Columbia, Canada

  • Charité - Universitätsmedizin Berlin, Campus Charité Mitte; Klinik für Psychiatrie und Psychotherapi

    Berlin, Germany

  • St. Josef and St. Elisabeth GmbH ; Klinikum Bochum, Zentralapotheke

    Bochum, Germany

  • Universitaetsklinikum Ulm

    Ulm, Germany

  • NIHR Welcome Trust Birmingham CRF - University Hospitals Birmingham; Department of Neuropsychiatry

    Birmingham, United Kingdom

  • University of Cambridge - John van Geest Centre for Brain Repair

    Cambridge, United Kingdom

  • Cardiff University School of Medicine; Institute of Psychological Medicine Clinical Neurosciences

    Cardiff, United Kingdom

  • Leonard Wolfson Experimental Neurology Centre

    London, United Kingdom

  • Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.